Detail akcie Iridex Corp online

Business Summary: IRIDEX Corporation is an ophthalmic medical technology company, which is focused on the development and commercialization of products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. The Company’s laser consoles products consist of Glaucoma, which includes Cyclo G6 laser and delivery devices used for the treatment of glaucoma; Medical Retina product line, which includes IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases, and its PASCAL Synthesis Photocoagulator for the treatment of retinal diseases; Surgical Retina, which includes OcuLight TX, OcuLight SL and OcuLight SLx laser photocoagulation systems. The Company’s laser probes products consist of Glaucoma, which include MicroPulse P3 Probe, G-Probe and G-Probe Illuminate, and Surgical Retina probes, which include EndoProbe family of products used in vitrectomy procedures.
Financial Summary: BRIEF: For the fiscal year ended 30 December 2023, IRIDEX Corp revenues decreased 9% to $51.9M. Net loss increased 27% to $9.6M. Revenues reflect United States segment decrease of 11% to $26.1M, Rest of the Americas segment decrease of 33% to $2.1M. Higher net loss reflects Selling expenses increase of 17% to $7.9M (expense), Stock-based Compensation in R&D increase of 40% to $217K (expense).